Introduction -Sarcoglycanopathies are rare inherited muscular dystrophies belonging to the group of autosomal recessive limb girdle muscular dystrophies (limb girdle muscular dystrophy type 2C) (Bushby and Beckmann, 1995) . Sarcoglycans (-, b-, -and -) are transmembrane proteins that form a complex that associates with dystrophin in the muscle fibre membrane (Ozawa et al., 1998) . Clinical expression of limb girdle muscular dystrophy type 2C is highly variable: the disease is rapidly progressive in 20-49% of cases with onset in the first decade of life, intermediate in 27-55% and milder in 13-25% (Ben Hamida et al., 1996; Merlini et al., 2000; Kefi et al., 2003) . Dilated cardiomyopathy is relatively frequent, particularly in advanced stages (Calvo et al., 2000) .
There is currently no specific treatment for limb girdle muscular dystrophy type 2C, but gene therapy might be an option in the future. In a preclinical mouse model based on -sarcoglycan (-SGC) gene disruption (Hack et al., 1998) , animals injected with an adeno-associated virus (AAV) vector expressed -SGC in the sarcolemma of muscle fibres and showed an overall improvement in their dystrophic histological pattern (Cordier et al., 2000) . These findings, together with reassuring complete safety studies in mice, led us to launch an open-label, dose-escalation, three-cohort (phase I) study of intramuscular delivery of replication-defective AAV (AAV1.des.hSGC) expressing -SGC. The goal was to examine the safety of AAV1 vector administration and exogenous -SGC expression.
Patients and methods

Patients
Nine patients (seven females and two males, average age 27 years, range 16-38 years; Table 1 ) were selected on the basis of the following criteria: (i) molecular genetic studies showing homozygous del525T mutation of the -SGC gene on chromosome 13; (ii) pre-inclusion muscle biopsy on dominant extensor carpi radialis (on Day À 30) showing no -SGC immunohistochemical staining; (iii) wheelchair dependent but with adequate extensor carpi radialis muscle bulk and strength (MRC 5 3 + ) for muscle biopsy and reliable strength assessment; and (iv) no severe cardiac dysfunction (ejection fraction 4 30%) or respiratory dysfunction (forced vital capacity 41000 ml and/or 430% of normal). Thirty days after vector administration (Day 30), muscle biopsy was performed at the injection site. The patients were tested at Days À30, 0, 15, 30, 60, 120 and 180 for maximal wrist extension strength by means of dynamometry, using standardized operating procedures (Romero et al., 2004) . MRI of the forearm was also performed at Days À30 and 15 with a Siemens Trio Tim device operating at 3T. The patients were offered regular interviews with a psychologist during the study, to provide support and to assess the psychological impact of trial participation.
All clinical, MRI and biological findings, including immunohistochemical findings on muscle biopsy specimens and immunological data, were analysed by a steering committee, including independent experts, who authorized the enrolment of the next patient. All nine enrolled patients completed the protocol.
The protocol was submitted to independent committees, as required by French legislation on clinical trials of gene therapy products 
Adeno-associated virus-1 vector preparation
The recombinant pseudotyped AAV1.des.h-SGC vector was produced in HEK293 cells by using the three-plasmid transfection protocol, as described elsewhere (Boutin et al., 2010) , with the following three GMP-manufactured, CsCl gradient-purified constructs, all containing an ampicillin resistance gene: (i) a pAAV1 plasmid containing the human -SGC gene sequence under the control of the desmin promoter, followed by a small segment of exon II, IVSII, exon III and the polyadenylation signal of the human b-globin gene sequence; (ii) a pLT-RC02 plasmid containing the full Cap coding region and some of the three sequences of the Rep region amplified from wild-type AAV1 viral stocks from the American Type Culture Collection (ATCC), and fused to the appropriate positions of the AAV2 Rep sequences in the parental AAV2 helper construct; and (iii) a pHGTI-Adeno1 plasmid generated by cloning the E2A, E4orf6 and VA RNA regions of the adenovirus genome into the pLitmus vector (New England Biolabs). Plasmid and virus production were performed by the Harvard Gene Therapy Initiative (HGTI) laboratory in CF-10 flasks. The production process included freeze/thaw cell lysis followed by benzonase and detergent treatment, and a two-step purification process based on an iodixanol gradient and column chromatography. The purified bulk eluate was formulated in Dulbecco's phosphate-buffered saline buffer with Calcium and Magnesium and sterile-filtered before freeze storage. Viral genomes were quantified by real-time polymerase chain reaction and vector titres were expressed as viral genomes per millilitre.
Vector administration
All nine patients received AAV1.des.h-SGC by injection into the extensor carpi radialis muscle of the non-dominant forearm during open surgery (skin incision 12-15 mm long) under local anaesthesia. AAV1.des.h-SGC was injected into the muscle through the aponeurosis (which was not incised), at a depth of 2-4 mm, with an insulin syringe and a 27-gauge needle, between two sutures (as marks) 1 cm apart, which were removed during the Day 30 muscle biopsy procedure. Subjects in Group 1 received a single injection of 3 Â 10 9 viral genomes in 100 ml. Subjects in Group 2 received a single injection of 1.5 Â 10 10 viral genomes in 100 ml. Subjects in Group 3 received three simultaneous injections of 1.5 Â 10 10 viral genomes, each in 100 ml (total 4.5 Â 10 10 viral genomes, 300 ml), forming a triangle of 2 mm at the incision site.
Muscle biopsy analysis
To examine the local effects of AAV1.des.h-SGC administration, a muscle biopsy specimen was collected from the injection site 30 days later (Day 30). The fragment was 10-15 mm long and 3-4 mm wide and was immediately frozen. The entire muscle fragment was serially sectioned on a cryostat and the sections were distributed, using a pre-established procedure, between histological examination and gene transfer evaluation (Romero et al., 2004) . Briefly, a series of 10 sections 20-mm thick was prepared for western blot (Romero et al., 2004) , followed by eight sections 10-mm thick for haematoxylin-eosin staining, five series of seven sections 8-mm thick for sarcoglycan and dystrophin immunohistochemistry (Romero et al., 2004) and markers of inflammation (CD4, CD8, CD20cy, MHC-class I, MHC-class II), 10 sections 20-mm thick for real-time polymerase chain reaction detection of AAV1 DNA and 10 sections 20-mm thick for real-time polymerase chain reaction detection of exogenous -SGC messenger RNA. This series was repeated three times. The primers used for the amplification of the vector DNA are located in the inverted terminal repeat region. The primers used for the amplification of messenger RNA specific to the transgene are located at the end of the transgene sequence and in the polyadenylation site; these primers allow the amplification of messenger RNA specific to the -SGC transgene without amplifying RNA specific to the endogenous -SGC gene.
Histopathological studies with haematoxylin-eosin and immunohistochemical staining were performed twice. The first examination consisted of a safety assessment before inclusion of the following patient. Then, at the end of the study, the anonymized and randomly distributed slides (from the injected muscle at Day 30 and from the contralateral non-injected muscle at Day À30) were examined blindly by a muscle pathologist independent of the steering committee and study staff. Finally, the percentage of -SGC stained fibres and the MHC-class I expression were evaluated automatically with Ellix were then compared with those obtained in the contralateral extensor carpi radialis muscle on Day À30. Furthermore, for MHC-class I quantification, we also used the biopsy specimens of three healthy subjects as negative controls and of three patients with definite polymyositis and ubiquitous MHC-class I expression as positive controls.
Immune responses to adeno-associated virus-1 and -sarcoglycan
The humoral response to AAV1 was measured by enzyme-linked immunosorbent assay on serial dilutions of heat-inactivated serum, as previously described (Boutin et al., 2010) . The humoral response to -SGC was measured by western blot on C2C12 cells overexpressing human -SGC. Neutralizing assay was performed as previously described (Boutin et al., 2010) . The neutralizing factor titre was recorded as the highest serum dilution that inhibited AAV transduction by 550% on HeLa cells. Cellular immune responses were evaluated with ELISPOT assays (Romero et al., 2004) . Briefly, frozen peripheral blood mononuclear cells were plated in interferon--precoated 96-well ELISPOT plates (Mabtech) and incubated in the presence of lentiviral vectors encoding the whole -SGC protein or the AAV1 VP1, VP2 and VP3 capsid proteins. Results were recorded as spot-forming units/10 6 cells.
Samples were considered positive for -SGG or VP1 if the ratio between the number of spots for a specific transgene and the corresponding control with lentiviral empty was 41.5 times (cut-off based on mean ratio of 32 negative donors + 3 SD 
Results
Tolerability of AAV1.des.h-SGC injection
The injections were well tolerated, with no physical or psychological adverse effects, except for an episode of fever that occurred on Day 3 in Patient 5 and resolved spontaneously within 48 h. No local inflammation or swelling was observed.
Muscle strength was stable during the 6-month follow-up period, as assessed by dynamometry, in both the injected and contralateral forearms (Fig. 1) haematoxylin-eosin staining and no immunohistochemical evidence of local inflammation (data not shown). MHC-class I expression on muscle fibres was stable (Fig. 2) . AAV1.des.h-SGC was detected by polymerase chain reaction in peripheral blood mononuclear cells collected from one patient (Patient 8), 12 and 24 h after administration (66 copies/4.5 Â 10 4 cells and 49 copies/3.6 Â 10 4 cells, respectively), before becoming undetectable at 48 h; and also in urine collected from another patient 24 h after administration (Patient 3, 4.4 Â 10 3 copies/ml), before becoming undetectable at 48 h.
Transgene expression
Thirty days after AAV1.des.h-SGC injection, AAV1 was detected by polymerase chain reaction in the injection-site muscle biopsy samples from all but one of the patients (Patient 4, Table 1 ). Gene therapy for -sarcoglycanopathy Fig. 3A ). Wild-type -SGC protein was also detected by western blot (Table 1 and Fig.  3B ) in Patient 9. -SGC expression was accompanied by the detection of SCG complexes (Fig. 3C) . No -SGC immunolabelling was detected in any of the Day À 30 biopsy specimens taken from the contralateral forearm (Fig. 3A) .
Immune responses to AAV1.des.h-SGC
Patients 2, 5 and 6 were found to have pre-existing anti-AAV1 neutralizing antibodies (Table 2 ). Patient 7 had seroconverted naturally by Day 0. The remaining five patients were AAV1-seronegative prior to AAV1.des.h-SGC administration. All five seronegative patients became AAV1-seropositive at various times after AAV1.des.h-SGC injection, but Patients 1, 3 and 4 did not develop neutralizing antibodies (Table 2) . Anti-AAV1 antibody titres increased after AAV1.des.h-SGC injection in all the pre-immunized patients (Table 2) . No anti--SGC antibodies were detected in any of the patients (data not shown). Patients 2 and 7 were found to be VP1-reactive by ELISPOT before AAV1.des.h-SGC injection, but both tested negative on Day 30 (Fig. 4) . Patient 8 had a positive cellular immune response to VP1 at all three time points (Days 30, 120 and 180) after AAV1.des.h-SGC injection, while Patient 6 was only positive on Day 180 (Fig. 4) . No anti--SGC cellular responses were detected by ELISPOT in any of the patients (data not shown).
Discussion
In this phase I trial, intramuscular injection of AAV1.des.h-SGC at the highest dose consistently induced exogenous -SGC expression, with no serious adverse effects. The low and intermediate doses induced little or no transgene expression, suggesting a dose-related effect. These findings were confirmed by (i) quantification assessed by densitometry; and (ii) real-time and blinded retrospective comparisons of immunohistochemically stained biopsy specimens from the injected extensor carpi radialis muscle and the contralateral uninjected extensor carpi radialis muscle, obtained 1 month after and 1 month before AAV1.des.h-SGC administration, respectively. Gene therapy holds promise for patients with a variety of inherited disorders, and proof of principle has been obtained in animal models. AAV is currently the most promising viral vector (for a review see Heilbronn and Weger, 2010) . Some phase I/II human gene therapy trials with AAV vectors and efficient gene transfer have been completed, notably in Leber's congenital amaurosis (with some clinical benefit) (Bainbridge et al., 2008; Cideciyan et al., 2008; Maguire et al., 2008 Maguire et al., , 2009 ), haemophilia B (Manno et al., 2003 (Manno et al., , 2006 and limb girdle muscular dystrophy type 2D (-SGC deficiency) (Mendell et al., 2009 . In the latter study, the efficacy demonstrated using the low dose precluded the need to expose patients to higher viral doses (Mendell et al., 2009) . The six treated patients received a local intramuscular injection of 3.25 Â 10 11 viral genomes (about seven times the highest dose used here) of an AAV1 vector carrying the -SGC gene under the control of a truncated muscle-specific muscle creatine kinase promoter. Immunohistochemical -SGC staining was more intense than in our study, with 57-62% of fibres positive (Mendell et al., 2009 ) and persisted for 6 months . This difference may be due to the use of a higher injected dose, but it should also be noted that at baseline, patients had detectable -SGC staining by immunohistochemistry or western blot (Mendell et al., 2009 . The use of different promoters might also have contributed to the observed difference in transgene expression.
No serious adverse effects have so far been noted in the 200-plus patients who have received different AAV subtypes, at different doses, via different routes and in different indications (Manno et al., 2003 (Manno et al., , 2006 Kaplitt et al., 2007; Moss et al., 2007; Bainbridge et al., 2008; Cideciyan et al., 2008; Maguire et al., 2008 Maguire et al., , 2009 Stroes et al., 2008; Brantly et al., 2009; Jaski et al., 2009; Mendell et al., 2009) . Nevertheless, transgene expression can be compromised by immune responses to AAV (Manno et al., 2006; and/or to the exogenous wild-type protein . We observed no signs of non-specific inflammatory reactions such as local pain, swelling, erythema or inflammatory marker elevation. Pre-existing anti-AAV neutralizing antibodies can limit transduction efficiency, both in humans (Manno et al., 2006; and in animal models (Riviere et al., 2006) . We have previously found that the prevalence of anti-AAV1 neutralizing antibodies is $50% in the general French population (Boutin et al., 2010) . Thus, the lack of detectable -SGC in Patients 2 and 5, who had neutralizing antibodies to AAV1 before AAV1.des.h-SGC injection, might have been due to this pre-existing immunity, as we have observed in mice after repeated intramuscular administration (Riviere et al., 2006) . In order to avoid this potential confounding factor, and with ethics committee approval, we decided to include only AAV-seronegative patients in the group receiving the highest dose of AAV1--SGC. All five previously seronegative patients developed anti-AAV1 antibodies, between 15 and 180 days after AAV1--SGC injection. Neutralizing antibodies were detected in only two patients (Patients 8 and 9). Pre-immunized patients exhibited a recall response (stronger and more rapid), suggesting a trigger effect. Regarding the cellular immune response mediated by cytotoxic CD8 + T cells, two patients with haemophilia B treated by hepatic artery injection of a gene therapy product (Manno et al., 2006) had a transient, self-limited elevation of liver enzymes, a concomitant decline in factor IX to pretreatment levels, and AAV capsid-specific CD8 + T cell expansion, suggesting immune destruction of transduced hepatocytes (Manno et al., 2006) . Similarly, patients with lipoprotein lipase deficiency receiving intramuscular injections of AAV1-lipoprotein lipase S447X (10 11 or 3 Â 10 11 viral genomes/kg) exhibited a loss of efficacy at later time points (18-31 months), possibly due to a T cell response to AAV1 capsid proteins (Stroes et al., 2008) . Thus, pre-existing memory T cells specific for AAV capsid proteins may lead to a loss of transgene expression by lysing transduced cells (Mingozzi et al., 2009) . In the study of six patients with limb girdle muscular dystrophy type 2D, an anti-capsid response was observed in three subjects after AAV1 vector injection (Mendell et al., 2009 . However, five patients exhibited MHC-class I antigen overexpression at the surface of their muscle fibres, as well as inflammatory cell infiltration, indicating a local cellular response to AAV and/or to the exogenous protein (Mendell et al., 2009 . Only one of our patients (Patient 8), who received the highest dose, had a persistently detectable cytotoxic T lymphocyte response, from Days 30 to 180. Contrary to previous studies, we observed no concomitant creatine kinase elevation, MHC-class I overexpression, or inflammatory infiltration. The cellular response in Patient 8 did not appear to correlate with the strength of the humoral response. This discrepancy in the frequency of detectable cellular immune responses in different clinical studies may be explained by differences in the AAV dose (Mingozzi et al., 2009) . Another important factor may be the quality (purity) of the vector preparation (Wright, 2009) . Finally, intramuscular AAV delivery is consistently more immunogenic than intravenous delivery (Toromanoff et al., 2010) .
Our findings represent proof of concept for -SGC replacement therapy in patients with limb girdle muscular dystrophy type 2C. Further research will be needed to achieve widespread vector delivery, using locoregional (Hegge et al., 2010) or, ultimately, systemic delivery of AAV -SGC vectors.
